{
  "events": [
    {
      "drug": "---",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "---",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "",
      "indication": "",
      "company": "[11.30.2025]",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2001-25-06",
      "source_url": "https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/"
    },
    {
      "drug": "",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2018-25-02",
      "source_url": "https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/"
    },
    {
      "drug": "",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2023-24-07",
      "source_url": "https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/"
    },
    {
      "drug": "ANX007",
      "indication": "",
      "company": "Annexon",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/g43692147/annexon-announces-presentations-highlighting-anx007-functional-and-structural-differentiation-in-g"
    },
    {
      "drug": "AVERSA",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/g43688524/nutriband-and-kindeva-drug-delivery-formalize-exclusive-development-partnership-for-aversa-fentany"
    },
    {
      "drug": "AZD1656",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/g43690749/conduit-pharmaceuticals-partners-with-charles-river-in-clinically-relevant-systemic-lupus-erythema"
    },
    {
      "drug": "BCDA-03",
      "indication": "",
      "company": "BioCardia",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/g43692141/biocardia-reports-completion-of-low-dose-cohort-enrollment-for-cardiallo-phase-iii-clinical-trial-"
    },
    {
      "drug": "BP1001-A",
      "indication": "",
      "company": "Bio-Path Holdings",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/g43690774/bio-path-holdings-provides-key-clinical-updates"
    },
    {
      "drug": "CGuard",
      "indication": "",
      "company": "InspireMD",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/g43688508/inspiremd-and-namsa-to-partner-on-cguardians-ii-pivotal-clinical-trial-of-the-cguard-prime-80-cm-c"
    },
    {
      "drug": "IDE397",
      "indication": "",
      "company": "IDEAYA Biosciences",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/n43687015/ideaya-announces-further-gilead-sciences-clinical-study-collaboration-evaluating-combination-of-tr"
    },
    {
      "drug": "Mevrometostat",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Mitapivat",
      "indication": "",
      "company": "Agios Pharmaceuticals",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/g43687696/agios-phase-3-activate-kids-study-of-mitapivat-in-children-with-pyruvate-kinase-pk-deficiency-not-"
    },
    {
      "drug": "Nipocalimab",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/n43691284/new-nipocalimab-data-published-in-mabs-journal-details-differentiated-molecular-design-clinical-pr"
    },
    {
      "drug": "Oncoprex",
      "indication": "",
      "company": "Genprex",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/n43691635/genprex-collaborators-find-nprl2-gene-therapy-using-oncoprex-delivery-system-is-a-potential-treatm"
    },
    {
      "drug": "RenovoCath",
      "indication": "",
      "company": "RenovoRx",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/b43690828/renovorx-highlights-promising-pre-clinical-data-abstract-tamp-therapy-platform-offers-potential-to"
    },
    {
      "drug": "Sabizabulin (VERACITY)",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/g43687694/veru-reports-fiscal-2025-first-quarter-financial-results-and-clinical-program-progress"
    },
    {
      "drug": "TCB008",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-13",
      "source_url": "https://www.benzinga.com/pressreleases/25/02/n43692157/tcbp-announces-successful-completion-of-cohort-a-in-the-achieve-clinical-trial"
    },
    {
      "drug": "5-in-1 meningococcal ABCWY",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-14",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Vimseltinib",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-17",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "FABHALTA",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-24",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "IZERVAY",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-26",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "ET-400",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-28",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Mirdametinib",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-02-28",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "FUROSCIX",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-06",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Neffy 1 mg",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-06",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "VTAMA",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-12",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Vutrisiran",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-23",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "TLX007-CDx",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-24",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "CARDAMYST",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-26",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Gepotidacin",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-26",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "CARDAMYST",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-27",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Diazoxide Choline Controlled-Release tablet",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-27",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Chenodiol",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-28",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Fitusiran",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-03-28",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Reproxalap",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-04-02",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "CABOMETYX",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-04-03",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "VYVGART SC pre-filled syringe",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-04-10",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Dupixent",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-04-18",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Opdivo plus Yervoy",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-04-21",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "TLX101-CDx",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-04-26",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Pz-cel",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-04-29",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "INZ-701",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-05-01",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Imetelstat",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-05-01",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Pelacarsen",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-05-01",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Simufilam",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-05-01",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "VLA15",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-05-01",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Nucala",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-05-07",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "ZORYVE",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-05-22",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "CTI-1601",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-07-01",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "IO102-IO103 + KEYTRUDA",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-07-01",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "Afrezza",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-09-01",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-24-20",
      "source_url": "https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/"
    },
    {
      "drug": "",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-25-20",
      "source_url": "https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/"
    },
    {
      "drug": "",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2025-54-00",
      "source_url": "https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/"
    },
    {
      "drug": "IMpactMF",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2026-01-01",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "SOTORASIB CODEBREAK 200",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2028-02-01",
      "source_url": "https://unusualwhales.com/fda-calendar"
    },
    {
      "drug": "",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "2028-24-08",
      "source_url": "https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/"
    },
    {
      "drug": "",
      "indication": "",
      "company": "names or tickers, events, date-wise or based on a date range. They are designed to serve as a \u2018one-stop shop\u2019 for data needs of investors, both existing and potential, to capitalize on the opportunities these catalysts throw up or cut the losses from an adverse development.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "may have made in the investigational therapy could go down the drain. Quite appropriately, investors punish the stock by selling it in droves.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "| Close \u25b2\u25bc | \u00b1% | Avg. Vol \u25b2\u25bc | Buy Stock |",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "to fund the review process.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "may roughly calculate a timeline based on the data of filing the regulatory application. If the company doesn\u2019t provide a timeline either, it is left to the investors to do the calculations.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "files for a regulatory application, the FDA takes up to 60 days to respond with an \u2018accepted for review\u2019 or \u2018refuse-to-file\u2019 decision.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "**HMPL-306 - (RAPHAEL)**",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "**HMPL-523 - (ESLIM-01)** BTD",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "**NurOwn** [View Clinical Trial Data](javascript:;)",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "**Paxalisib (PNOC022)** [View Clinical Trial Data](javascript:;)",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "**RYONCIL (remestemcel-L) - (MSB-GVHD001)**",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "**Roflumilast Cream (ARQ-151) - (INTEGUMENT-1 and INTEGUMENT-2)**",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "**SULANDA (surufatinib)**",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "**Sovleplenib - (ESLIM-02)**",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "**Tumor Treating Fields (TTFields) - (LUNAR)** [View Clinical Trial Data](javascript:;)",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "---",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.biopharmcatalyst.com/calendars/fda-calendar"
    },
    {
      "drug": "User Fee Act date, in short, PDUFA date, refers to the date/period by which the FDA is mandated to give its verdict on the regulatory application filed by the sponsor company. The verdict can be an \u2018approved\u2019 decision, or a \u2018complete response letter\u2019 or a delay due to reasons specific to the company or extraneous to the company.",
      "indication": "",
      "company": "or extraneous to the company.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "With FDA Nod For Saxenda](https://www.benzinga.com/news/health-care/25/08/47397079/teva-launches-generic-glp-1-weight-loss-drug-with-fda-nod-for-saxenda)",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "application, or NDA, supplemental NDA, Biologic License Application, or BLA, supplemental BLA, Premarket Approval Application, or Premarket Notification 510(k), etc",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "development is perceived by the market as an incremental step in bringing the company closer to that distant goal of marketing a potential blockbuster drug that could fetch it billions in revenues. This explains the huge positive move in a stock when a company reports a positive clinical readout.",
      "indication": "",
      "company": "closer to that distant goal of marketing a potential blockbuster drug that could fetch it billions in revenues. This explains the huge positive move in a stock when a company reports a positive clinical readout.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "development, which usually takes about 10-15 years, on the promise of generating future returns.",
      "indication": "",
      "company": "and as a result generate revenues in the form of licensing revenues. So, it will be years of investment (time money and efforts) into drug development, which usually takes about 10-15 years, on the promise of generating future returns.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "ingredients are being made etc.",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "May 15, 2025",
      "source_url": "https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/"
    },
    {
      "drug": "Application (NDA) | 2025-09-12 | PDUFA Date | BioCryst Pharmaceuticals, Inc. FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025\u2013 [View](https://www.benzinga.com/pressreleases/25/05/g45402162/biocryst-announces-fda-acceptance-of-nda-for-orladeyo-berotralstat-oral-granules-in-patients-with-) | [Get Alert](https://www.benzinga.com/profile/portfolio/?action=login&utm_source=calendars) |",
      "indication": "",
      "company": "\u25b2\u25bc | Price \u25b2\u25bc | % change \u25b2\u25bc | Name and Treatment \u25b2\u25bc | Status \u25b2\u25bc | Catalyst Date \u25b2\u25bc | Catalyst \u25b2\u25bc | Description \u25b2\u25bc | Get Alert |",
      "pdufa_date": "| BioCryst Pharmaceuticals, Inc. FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025\u2013 [View](https://www.benzinga.com/pressreleases/25/05/g45402162/biocryst-announces-fda-acceptance-of-nda-for-orladeyo-berotralstat-oral-granules-in-patients-with-) | [Get Alert](https://www.benzinga.com/profile/portfolio/?action=login&utm_source=calendars) |",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "| End Date | Meeting | Contributing Office | Center |",
      "source_url": "https://www.fda.gov/advisory-committees/advisory-committee-calendar"
    }
  ]
}